- Home
- CDLR vs TARS Comparison
CDLR vs TARS Comparison
Compare CDLR & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDLR
- TARS
- Stock Information
- Founded
- CDLR 2008
- TARS 2016
- Country
- CDLR Denmark
- TARS United States
- Employees
- CDLR N/A
- TARS N/A
- Industry
- CDLR
- TARS Medicinal Chemicals and Botanical Products
- Sector
- CDLR
- TARS Health Care
- Exchange
- CDLR Nasdaq
- TARS Nasdaq
- Market Cap
- CDLR 1.9B
- TARS 1.7B
- IPO Year
- CDLR N/A
- TARS 2020
- Fundamental
- Price
- CDLR $20.98
- TARS $50.60
- Analyst Decision
- CDLR
- TARS Strong Buy
- Analyst Count
- CDLR 0
- TARS 7
- Target Price
- CDLR N/A
- TARS $67.14
- AVG Volume (30 Days)
- CDLR 43.7K
- TARS 671.0K
- Earning Date
- CDLR 08-26-2025
- TARS 11-12-2025
- Dividend Yield
- CDLR N/A
- TARS N/A
- EPS Growth
- CDLR N/A
- TARS N/A
- EPS
- CDLR 0.78
- TARS N/A
- Revenue
- CDLR $546,159,718.00
- TARS $295,521,000.00
- Revenue This Year
- CDLR $116.02
- TARS $33,170.29
- Revenue Next Year
- CDLR $80.90
- TARS N/A
- P/E Ratio
- CDLR $6.72
- TARS N/A
- Revenue Growth
- CDLR 277.89
- TARS 254.45
- 52 Week Low
- CDLR $17.37
- TARS $30.23
- 52 Week High
- CDLR $28.75
- TARS $59.76
- Technical
- Relative Strength Index (RSI)
- CDLR 48.91
- TARS 42.03
- Support Level
- CDLR $20.85
- TARS $48.20
- Resistance Level
- CDLR $21.70
- TARS $59.76
- Average True Range (ATR)
- CDLR 0.33
- TARS 2.00
- MACD
- CDLR -0.01
- TARS -1.44
- Stochastic Oscillator
- CDLR 55.83
- TARS 20.76
About CDLR Cadeler AS
Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.